Journal article · 2026 · Open access

Impact of Food and Beverage on Enlicitide Pharmacokinetics and LDL ‐C Lowering

Douglas G. Johns, Maja Skataric, Susan Zhou, Ferdous Gheyas, Ednan K. Bajwa, Puja Banka, Filippos Kesisoglou, Allen Hunt, David Bruce, Corey Anderson, Helen Manthos, Jonathan D. Pollock and 11 more

Clinical Pharmacology & Therapeutics · Published 6 November 2026 · DOI 10.1002/cpt.70541

Open PDFView at the publisherCite this paper

In brief

“Impact of Food and Beverage on Enlicitide Pharmacokinetics and LDL ‐C Lowering” is a 2026 journal article by Douglas G. Johns and 22 co-authors, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 0 citations as of 17 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Clinical Pharmacology & Therapeutics.

Citations
0
References
34
Authors
23

Abstract

Enlicitide decanoate is a macrocyclic peptide first-in-class oral PCSK9 inhibitor that lowers LDL-C, with maximal efficacy achieved when administered on an empty stomach. This work characterizes the effects of food, pre-dose fasting duration (2-8 hours), water volume, common beverages (black coffee and plain tea), and other real-world scenarios on enlicitide exposure and predicts the impact on clinical efficacy. Three phase I, open-label, crossover studies in healthy participants evaluated the effects of these conditions on enlicitide exposure following a single 20 mg dose. Enlicitide steady-state exposure and corresponding LDL-C reductions under various conditions were predicted using population pharmacokinetic and exposure-response models. Administration of enlicitide 30 minutes after a high-fat meal resulted in an approximately 48% reduction in steady-state AUC and delayed absorption compared with fasted conditions (median Tmax ~8 hours vs. 0.5-1 hour). Increasing pre-dose fasting duration from 2 to 8 hours increased exposure. Water volume, black coffee or plain tea had no meaningful effect on enlicitide exposure. Model-predicted LDL-C reductions remained robust across various conditions, with LDL-C reductions of approximately 64% under fasted conditions, 62% to 63% when occasionally administered with food or if a dose is occasionally missed, 60% with black coffee or plain tea, and 59% following a 4-hour fast. These data support the recommended dosing and administration instructions for enlicitide, which are expected to provide ~60% LDL-C reduction, as seen in the enlicitide phase III clinical trials. Furthermore, these findings highlight the pharmacokinetic forgiveness potential of enlicitide, suggesting that occasional departures from the recommended dosing or sporadic lapses in compliance may be tolerated with minimal impact on efficacy.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Johns, D. G., Skataric, M., Zhou, S., Gheyas, F., Bajwa, E. K., Banka, P., Kesisoglou, F., Hunt, A., Bruce, D., Anderson, C., Manthos, H., Pollock, J. D., Donabella, P. J., Thompson, C., Freire, D., Giang, K., Pietrantonio, F., Wolford, D. G., Basak, P., . . . Younis, I. R. (2026). Impact of Food and Beverage on Enlicitide Pharmacokinetics and LDL ‐C Lowering. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70541

MLA 9

Johns, Douglas G., et al. “Impact of Food and Beverage on Enlicitide Pharmacokinetics and LDL ‐C Lowering.” Clinical Pharmacology & Therapeutics, 2026. https://doi.org/10.1002/cpt.70541.

Chicago

Johns, Douglas G., Maja Skataric, Susan Zhou, Ferdous Gheyas, Ednan K. Bajwa, Puja Banka, Filippos Kesisoglou, et al. 2026. “Impact of Food and Beverage on Enlicitide Pharmacokinetics and LDL ‐C Lowering.” Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70541.

Harvard

Johns, D. G. et al. (2026) ‘Impact of Food and Beverage on Enlicitide Pharmacokinetics and LDL ‐C Lowering’, Clinical Pharmacology & Therapeutics. doi:10.1002/cpt.70541.

IEEE

D. G. Johns et al., “Impact of Food and Beverage on Enlicitide Pharmacokinetics and LDL ‐C Lowering,” Clinical Pharmacology & Therapeutics, 2026, doi: 10.1002/cpt.70541.

BibTeX

@article{johns2026impact,
  title     = {{Impact of Food and Beverage on Enlicitide Pharmacokinetics and LDL ‐C Lowering}},
  author    = {Johns, Douglas G. and Skataric, Maja and Zhou, Susan and Gheyas, Ferdous and Bajwa, Ednan K. and Banka, Puja and Kesisoglou, Filippos and Hunt, Allen and Bruce, David and Anderson, Corey and Manthos, Helen and Pollock, Jonathan D. and Donabella, Paul J and Thompson, Campbell and Freire, Daniel and Giang, Kiet and Pietrantonio, Frank and Wolford, Dennis G. and Basak, Piyali and Pistilli, Maxwell and Kantesaria, Bhavna S. and Kothare, Prajakti A. and Younis, Islam Rasem},
  journal   = {Clinical Pharmacology \& Therapeutics},
  year      = {2026},
  doi       = {10.1002/cpt.70541},
  url       = {https://doi.org/10.1002/cpt.70541}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health

  • PCSK9 inhibitors
  • food-drug interactions
  • high-fat meal
  • fasting duration
  • drug absorption
  • LDL cholesterol lowering
  • exposure-response modeling
  • population pharmacokinetics

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Johns, D. G., Skataric, M., Zhou, S., Gheyas, F., Bajwa, E. K., Banka, P., Kesisoglou, F., Hunt, A., Bruce, D., Anderson, C., Manthos, H., Pollock, J. D., Donabella, P. J., Thompson, C., Freire, D., Giang, K., Pietrantonio, F., Wolford, D. G., Basak, P., . . . Younis, I. R. (2026). Impact of Food and Beverage on Enlicitide Pharmacokinetics and LDL ‐C Lowering. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70541

How many times has this paper been cited?

0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Clinical Pharmacology & Therapeutics: sign in and open the PDF from this page.

Who wrote this paper?

Douglas G. Johns, Maja Skataric, Susan Zhou, Ferdous Gheyas, Ednan K. Bajwa, Puja Banka, Filippos Kesisoglou, Allen Hunt, David Bruce, Corey Anderson, Helen Manthos, Jonathan D. Pollock and 11 more.

What is the DOI of this paper?

10.1002/cpt.70541, permanently at https://doi.org/10.1002/cpt.70541. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.